Company intelligence / Profile preview

Cardiovalve

Ownership: Private
Employees: ~40
Development stage: Phase 1

Overview

Cardiovalve has developed a novel transfemoral transcatheter heart valve replacement system for both mitral and tricuspid valves. The device avoids open-heart surgery by using a minimally invasive approach. It has shown promising early clinical results with high procedural success rates and durable implants maintaining clinical benefit for over two years in initial patients. The system received FDA Breakthrough Device designation for the tricuspid indication and has ongoing early feasibility studies in the US and Europe[2][5].

Therapeutic areas: Cardiovascular
Modalities: DeviceBiologic
Industry: Implantable Medical Devices

Partnerships

None specifically disclosed; collaboration with leading hospitals for clinical trials[5]

Beyond the preview

Go deeper on Cardiovalve.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardiovalve.

Explore the full profile